Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.

Study Overview
=================
Brief Summary
-----------------
The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing

Official Title
-----------------
Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease. Identification de Biomarqueurs de SPondylArthrite Chez Les Patients Atteints de Maladie de CROhn présents Dans le MICrobiote fécal.

Conditions
-----------------
Crohn Disease, Spondyloarthritis

Intervention / Treatment
-----------------
* Other: Microbiota Sequencing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years. Patients will be recruited according to 3 groups: Patients with Crohn's disease and axial spondyloarthritis according to the criteria below. Patients with Crohn's disease (MC patients) with a diagnosis established according to clinical, biological criteria, radiological, endoscopic and / or histological studies for 3 months. With diagnosis of exclusion of a spondyloarthritis on criteria ASAS and / or New York modified. Patients with axial spondyloarthritis (SpA patients) with a diagnosis based on modified ASAS and / or New York criteria with exclusion diagnosis of Crohn's disease. Patient with the ability to give free and express informed consent. Exclusion Criteria: History of colonic resection Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (Temporary contraindication = removal possible before colic or first bowel preparation after the start of colonic preparation). Ostomy at the time of sampling BMI> 30 extreme diet unbalanced diabetes Pregnant woman Patient under guardianship, under curatorship or under the protection of justice Contacts/Locations Central Contact

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Crohn's disease<br>Patients suffering from established Crohn 's disease without spondyloarthritis | Other: Microbiota Sequencing<br>* virome, bacteriome, fungome NGS sequencing<br>|
| Other: Spondyloarthritis<br>Patients with established spondyloarthritis without Crohn 's disease | Other: Microbiota Sequencing<br>* virome, bacteriome, fungome NGS sequencing<br>|
| Other: Crohn + spondyloarthritis<br>Patients suffering from both spondyloarthritis and Crohn 's disease | Other: Microbiota Sequencing<br>* virome, bacteriome, fungome NGS sequencing<br>|
| Other: Healthy controls<br>Patients without spondyloarthritis and Crohn 's disease | Other: Microbiota Sequencing<br>* virome, bacteriome, fungome NGS sequencing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alpha and Beta diversity of Fecal bacteriome | Alpha (number of species) and Beta diversity (distribution of species) | + 6 months | 
| Alpha and Beta diversity of Fecal fungome | Alpha (number of species) and Beta diversity (distribution of species) | + 6 months | 
| Alpha and Beta diversity of Fecal virome | Alpha (number of species) and Beta diversity (distribution of species) | + 6 months |